{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":7,"youtube":4,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04513717\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"PREDICT-RT","nct_id":"NCT04513717","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=predict-rt-nct04513717. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin, histrelin, or relugolix and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity. Patients undergo bone scan, PET scan, CT scan, and MRI at screening and as clinically indicated and may optionally undergo blood sample collection throughout the study.","label":"Arm I (de-intensification study)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin, histrelin, or relugolix and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo bone scan, PET scan, CT scan, and MRI at screening and as clinically indicated and may optionally undergo blood sample collection throughout the study.","label":"Arm II (de-intensification study)","type":"EXPERIMENTAL"},{"description":"Patients undergo RT over 2-11 weeks and receive ADT as in Arm I. Patients undergo bone scan, PET scan, CT scan, and MRI at screening and as clinically indicated and may optionally undergo blood sample collection throughout the study.","label":"Arm III (intensification study)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin, histrelin, or relugolix) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity. Patients undergo bone scan, PET scan, CT scan, and MRI at screening and as clinically indicated and may optionally undergo blood sample collection throughout the study.","label":"Arm IV (intensification study)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2038-12-31","type":"ESTIMATED"},"conditions":["Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":{"count":2753,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Apalutamide","otherNames":["ARN 509","ARN-509","ARN509","Erleada","JNJ 56021927","JNJ-56021927"],"type":"DRUG"},{"name":"Bicalutamide","otherNames":["Casodex","Cassotide","Cosudex","ICI 176,334","ICI 176334","Utamide"],"type":"DRUG"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Scan","otherNames":["Bone Scintigraphy"],"type":"PROCEDURE"},{"name":"Buserelin","otherNames":["6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)","BSRL","Busereline","Etilamide","HOE 766","HOE-766","HOE766","ICI 123215","ICI-123215","ICI123215","S74 6766","S74-6766","S746766","Tiloryth"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Degarelix","otherNames":["ASP 3550","ASP-3550","ASP3550","FE 200486","FE-200486","FE200486","Firmagon"],"type":"DRUG"},{"name":"Flutamide","otherNames":["4'-Nitro-3'-trifluoromethylisobutyranilide","Apimid","Cebatrol","Chimax","Cytomid","Drogenil","Euflex","Eulexine","Flucinom","Flucinome","Flugerel","Fluken","Flulem","FLUT","Fluta-Gry","Flutabene","Flutacan","Flutamex","Flutamin","Flutan","Flutaplex","Fugerel","Grisetin","Niftolide","Oncosal","Profamid","Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-","Prostacur","Prostadirex","Prostica","Prostogenat","Sch 13521","Tafenil","Tecnoflut","Testotard"],"type":"DRUG"},{"name":"Goserelin","otherNames":["ICI-118630"],"type":"DRUG"},{"name":"Histrelin","otherNames":[],"type":"DRUG"},{"name":"Leuprolide","otherNames":["Leuprorelin"],"type":"DRUG"},{"name":"Magnetic Resonance Elastography","otherNames":["MRE"],"type":"PROCEDURE"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"},{"name":"Relugolix","otherNames":["N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea","Orgovyx","Relumina","TAK 385","TAK-385","TAK385"],"type":"DRUG"},{"name":"Triptorelin","otherNames":["6-D-Tryptophan-LH-RH","6-D-Tryptophanluteinizing Hormone-releasing Factor","AY 25650","AY-25650","AY25650","CL 118532","CL-118,532","CL-118532","CL118532","Detryptoreline"],"type":"DRUG"}],"last_update":"2026-08-17","lead_sponsor":"NRG Oncology","official_title":"Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Metastasis-free survival (MFS)","timeFrame":"From randomization to the date of detection of distant metastasis on standard imaging or date of death from any cause, assessed up to 13 years"},{"measure":"Sexual quality of life (De-intensification study)","timeFrame":"Up to 13 years"},{"measure":"Hormonal quality of life (De-intensification study)","timeFrame":"Up to 13 years"},{"measure":"Fatigue (Intensification study)","timeFrame":"Up to 13 years"}],"references":[],"start_date":{"date":"2021-01-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","url":"https://clinicaltrials.gov/study/NCT04513717"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/predict-rt-nct04513717"}